Trial 6: randomized study of prolonged chemotherapy, immunotherapy, and chemoimmunotherapy as an adjuvant to surgery for stage I and II melanoma: a progress report.
WHO clinical trial 6 studies the effect of long-term adjuvant therapy (chemotherapy, immunotherapy, and chemoimmunotherapy) after radical surgery in malignant melanoma with high risk of recurrence. The randomized study has been running for 67 months with 845 patients. This intermediate report seems to indicate that, concerning the relapse-free period, adjuvant treatment appears superior to surgery alone. However, no significant difference in the duration of survival is evident among the four treatment groups.
D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D009163:Mycobacterium bovis / Q000276:immunology
D003606:Dacarbazine